Workboat Indexes

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Topics Stocks

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million ↗

Today 8:36 EST

Via Benzinga

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug ↗

Today 7:51 EST

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.

Topics Government

These S&P500 stocks are moving in today's session ↗

December 23, 2025

Via Chartmill

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗

December 22, 2025

Gilead Sciences to Present at Upcoming Investor Conference

December 22, 2025

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes ↗

December 22, 2025

Via Benzinga

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 22, 2025

Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal ↗

December 20, 2025

Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.

Via Benzinga

Topics Government

Why Gilead Sciences (GILD) Stock Is Up Today

December 19, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive...

Via StockStory

Topics Earnings

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Via Investor's Business Daily

Topics Government Stocks

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 19, 2025

Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income ↗

December 19, 2025

Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts.

Via Chartmill

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Topics Economy Government

December 18, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

Topics Government World Trade

December 17, 2025

Via Benzinga

Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗

December 15, 2025

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Via Benzinga

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗

December 15, 2025

Via MarketBeat

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

December 15, 2025

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed.

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗

December 12, 2025

Via Investor's Business Daily

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗

December 12, 2025

Gilead Sciences (GILD) presents a strong value investing case, trading at a discount to its industry with high profitability, no debt, and improving earnings growth forecasts.

Via Chartmill

3 Profitable Stocks We Keep Off Our Radar

December 10, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

December 09, 2025

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

What Does the Market Think About Gilead Sciences Inc? ↗

December 08, 2025

Via Benzinga

December 07, 2025

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 06, 2025